Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
October 26, 2020 at 04:53 am EDT
Share
DGAP Voting Rights Announcement: Epigenomics AG
Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
26.10.2020 / 09:53
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Notification of Major Holdings
1. Details of issuer
Name:
Epigenomics AG
Street:
Geneststraße 5
Postal code:
10829
City:
Berlin Germany
Legal Entity Identifier (LEI):
549300X1C4U862NDLN97
2. Reason for notification
X
Acquisition/disposal of shares with voting rights
Acquisition/disposal of instruments
Change of breakdown of voting rights
Other reason:
3. Details of person subject to the notification obligation
Legal entity: Morgan Stanley City of registered office, country: Wilmington, Delaware, United States of America (USA)
4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
Morgan Stanley & Co. LLC
5. Date on which threshold was crossed or reached:
19 Oct 2020
6. Total positions
% of voting rights attached to shares (total of 7.a.)
% of voting rights through instruments (total of 7.b.1 + 7.b.2)
Total of both in % (7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New
9.91 %
0.03 %
9.94 %
47129846
Previous notification
11.60 %
0.03 %
11.64 %
/
7. Details on total positions a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN
Absolute
In %
Direct (Sec. 33 WpHG)
Indirect (Sec. 34 WpHG)
Direct (Sec. 33 WpHG)
Indirect (Sec. 34 WpHG)
DE000A11QW50
0
4670515
0.00 %
9.91 %
Total
4670515
9.91 %
b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Voting rights absolute
Voting rights in %
Right of recall over securities lending agreements
at any time
at any time
15838
0.03 %
Total
15838
0.03 %
b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Cash or physical settlement
Voting rights absolute
Voting rights in %
0
0.00 %
Total
0
0.00 %
8. Information in relation to the person subject to the notification obligation
Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X
Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:
Name
% of voting rights (if at least 3% or more)
% of voting rights through instruments (if at least 5% or more)
Total of both (if at least 5% or more)
Morgan Stanley
%
%
%
Morgan Stanley Capital Management, LLC
%
%
%
Morgan Stanley Domestic Holdings, Inc.
%
%
%
Morgan Stanley & Co. LLC
9.66 %
%
9.68 %
-
%
%
%
Morgan Stanley
%
%
%
Morgan Stanley Capital Management, LLC
%
%
%
Morgan Stanley Domestic Holdings, Inc.
%
%
%
Morgan Stanley & Co. LLC
%
%
%
Prime Dealer Services Corp.
%
%
%
-
%
%
%
Morgan Stanley
%
%
%
E*TRADE Financial, LLC
%
%
%
ETCM Holdings, LLC
%
%
%
E*TRADE Securities LLC
%
%
%
9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)
Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights
Proportion of instruments
Total of both
%
%
%
10. Other explanatory remarks:
The notification was triggered due to a disposal of client securities over which Morgan Stanley & Co. LLC had a right of use.
Date
23 Oct 2020
26.10.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution